Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance

Obstructive Jaundice Clinical Trial

Official title:

The Preventive Effects of Pre-treatment With Methylene Blue for Vascular Paralysis of the Patients With Obstructive Jaundice During Operation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03406676
• Other study ID #: MZK002
• Status: Recruiting
• Phase: N/A
• First received: January 4, 2018
• Last updated: January 22, 2018
• Start date: August 1, 2017
• Est. completion date: October 30, 2018

Study information

• Verified date: January 2018
• Source: Southwest Hospital, China
• Contact: Ning Jiaolin, Doctor
• Phone: 0086-15808014085
• Email: Njiaolin1976[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the effects of pre-treatment with methylene blue on reduced perioperative vascular resistance in patients with obstructive jaundice.

Description:

Hemodynamic characteristics of patients with obstructive jaundice are high cardiac output, low peripheral vascular resistance. The molecular basis for this feature is the increased production of NO. Methylene blue can increase peripheral resistance, the mechanism is: methylene blue is an oxidoreductase inhibitor, can inhibit the increased production of NO in the vascular endothelium, thereby increasing peripheral vascular resistance.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: October 30, 2018
• Est. primary completion date: October 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Aged between 18-60 years;

2. American Society of Anesthesiologists(ASA) grade I~III;

3. TBIL>ULN and TBA>ULN; The patients with obstructive jaundice.

Exclusion Criteria:

1. Organs dysfunction(heart,lungs and etc);

2. Mental disorders;

3. in other clinical trial.

Related Conditions & MeSH terms

• Jaundice
• Jaundice, Obstructive
• Obstructive Jaundice

Intervention

Drug:
• Methylene Blue
2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.

Locations

Country	Name	City	State
China	Southwest Hospital	Chongqing	Chongqing
China	Southwest Hospital	Chongqing	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Southwest Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peripheral vascular resistance	the dose of vasoconstrictors used to Maintain Peripheral vascular resistance in the normal range (800 ~ 1200dyns / cm5)	through operation completion, an average of 6 hours